<DOC>
	<DOCNO>NCT01562977</DOCNO>
	<brief_summary>The purpose study determine efficacy rituximab , gemcitabine , oxaliplatin dexametasone ( R-GemOx ) chemotherapy schedule .</brief_summary>
	<brief_title>Study Evaluate Efficacy Tolerance R-GemOx DLBCL MCL</brief_title>
	<detailed_description>The purpose study determine efficacy ( overall response rate ( ORR ) complete response ) tolerance toxicity rituximab , gemcitabine , oxaliplatin dexametasone ( R-GemOx ) chemotherapy schedule .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>1 . Age â‰¥ 18 year . 2 . DLBCL MCL diagnose patient primary resistance relapse eligible intensification chemotherapy follow Autologous stem cell transplantation ( ASCT ) age , comorbidity previous ASCT . 3 . Any IPI ECOG , capable understanding nature trial . 4 . Writtern Informed Consent . 1 . Nursing pregnant lactation period woman , fertile age adult use effective contraceptive method . 2 . CNS lymphoma patient . 3 . Patients severa renal ( creatinine &gt; 2,5 UNL ) hepatic ( Bilirrubin ALT/AST &gt; 2,5 UNL ) impairement provide disease 4 . HIV positive patient . 5 . Serious psychiatric disease patient could interfere skill understand study ( include alcoholism drug addiction ) . 6 . Murine proteins component medicine study hypersensitivity patient . 7 . Patients receive 2 therapeutic previous line . ( previous ASCT patient , induction conditioning TAPH treatment consider single line therapy ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>